Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD - Get Free Report) were up 2.4% during trading on Thursday . The stock traded as high as $22.85 and last traded at $22.67. Approximately 19,929 shares changed hands during mid-day trading, a decline of 77% from the average daily volume of 87,609 shares. The stock had previously closed at $22.13.
Analyst Upgrades and Downgrades
TVRD has been the subject of several research analyst reports. Piper Sandler began coverage on Tvardi Therapeutics in a research report on Thursday, June 12th. They issued an "overweight" rating and a $78.00 price objective for the company. Oppenheimer initiated coverage on shares of Tvardi Therapeutics in a research note on Wednesday, May 21st. They issued an "outperform" rating and a $65.00 price objective for the company. Cantor Fitzgerald started coverage on shares of Tvardi Therapeutics in a report on Friday. They set an "overweight" rating and a $52.00 price objective on the stock. Finally, Wall Street Zen raised shares of Tvardi Therapeutics to a "hold" rating in a report on Saturday, May 24th.
Read Our Latest Research Report on TVRD
Tvardi Therapeutics Stock Performance
Tvardi Therapeutics Company Profile
(
Get Free Report)
Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Recommended Stories
Before you consider Tvardi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tvardi Therapeutics wasn't on the list.
While Tvardi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
